Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer
Patients with esophagogastric cancer have poor prognoses in spite of the best available
therapies. Patients are debilitated and may not tolerate, or may progress, on standard …
therapies. Patients are debilitated and may not tolerate, or may progress, on standard …
ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago-gastric cancer, final results of an AGITG …
N Tebbutt, T Sourjina, A Strickland… - Journal of Clinical …, 2007 - ascopubs.org
4528 Background: Docetaxel (T), cisplatin (C) and 5FU (F) are active agents in esophago-
gastric cancer. A recent phase III study evaluating 3-weekly TCF demonstrated a survival …
gastric cancer. A recent phase III study evaluating 3-weekly TCF demonstrated a survival …
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer
M Roberto, A Romiti, CE Onesti, C D'Antonio… - Anti-Cancer …, 2016 - journals.lww.com
In recent years, metronomic chemotherapy, consisting of continuous administration of low
doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of …
doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of …
Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study
D Evans, T Miner, D Iannitti, P Akerman… - Cancer …, 2007 - Taylor & Francis
Purpose: A Phase I investigation of docetaxel, carboplatin, and capecitabine at our
institution demonstrated the safety and tolerability of this regimen in patients with metastatic …
institution demonstrated the safety and tolerability of this regimen in patients with metastatic …
[引用][C] Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial
G Chong, D Cunningham - Clinical Oncology, 2005 - clinicaloncologyonline.net
The therapeutic options available for the treatment of advanced oesophagogastric cancer
are numerous. However, relatively few randomised trials can provide evidence-based …
are numerous. However, relatively few randomised trials can provide evidence-based …
Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (EG) carcinoma having progressed or relapsed within 3 months of platinum …
L Assersohn, AR Norman, G Chong… - Journal of Clinical …, 2005 - ascopubs.org
4170 Background: To assess the efficacy and toxicity of a 3-weekly regimen containing
capecitabine combined with irinotecan (CapeIri) in refractory or relapsed EG carcinomas …
capecitabine combined with irinotecan (CapeIri) in refractory or relapsed EG carcinomas …
Phase I study of docetaxel, oxaliplatin, and capecitabine as first-line therapy to patients with advanced gastroesophageal cancer
KR Schønnemann, M Andersen, M Yilmaz… - Journal of Clinical …, 2009 - ascopubs.org
e15613 Background: Previously, epirubicin, cisplatin, and 5-FU (ECF) were often
recommended as first line therapy to patients (pts) with advanced gastro-esophageal cancer …
recommended as first line therapy to patients (pts) with advanced gastro-esophageal cancer …
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX …
NC Tebbutt, MM Cummins, T Sourjina… - British journal of …, 2010 - nature.com
Background: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to
better survival than does standard therapy in patients with oesophagogastric cancer, but …
better survival than does standard therapy in patients with oesophagogastric cancer, but …
Single-center experience with paclitaxel (T), carboplatin (C), and capecitabine (X) in the treatment of advanced esophagogastric cancer.
CA Ruoff, B Hong, BH Kaplan, S Pollack - 2013 - ascopubs.org
116 Background: Epirubicin, cisplatin, and 5-FU (ECF) improves overall survival for
advanced esopgagogastric adenocarcinoma compared with other protocols but is …
advanced esopgagogastric adenocarcinoma compared with other protocols but is …
[HTML][HTML] Capecitabine and oxaliplatin for advanced esophagogastric cancer
D Cunningham, N Starling, S Rao… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …